em 523 has been researched along with Diabetes Mellitus, Type 2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, N; Baba, S; Inui, A; Kasuga, M; Miyamoto, M; Morimoto, S; Nakajima, Y; Ohmoto, A; Okano, H; Ueno, N | 1 |
1 other study(ies) available for em 523 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
EM523L, a nonpeptide motilin agonist, stimulates gastric emptying and pancreatic polypeptide secretion.
Topics: Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Erythromycin; Evaluation Studies as Topic; Female; Gastric Emptying; Gastrointestinal Agents; Humans; Male; Middle Aged; Motilin; Pancreatic Polypeptide | 1996 |